Michael Walls, MD
Cardiovascular Disease · Indianapolis, INNPI 1497877526
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (46.0%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Heartflow, Inc. accounts for 90.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2023 at $1,330 and has fallen 91.4% since, to $115 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.
Across 22 payments — averaging $99.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- Boston Scientific$128
- Novartis$62
- Amgen$21
Across 1 payment — averaging $500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Heartflow, Inc.$500
What the payments were for
- Consulting fees$30614%
- Travel & lodging$87640%
- Food & beverage$1,00846%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 16 | $1,978 |
| Boston Scientific | 2 | $128 |
| Novartis | 3 | $62 |
| Amgen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$1,641
- WATCHMAN Access System$115
How this compares
$2,190 in reported general payments places this provider in the 45th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 437 | $543,837 |
| EntrestoSacubitril/Valsartan | 219 | $255,741 |
| JardianceEmpagliflozin | 185 | $193,560 |
| XareltoRivaroxaban | 98 | $142,112 |
| Repatha SureclickEvolocumab | 58 | $87,811 |
| MultaqDronedarone Hcl | 30 | $35,561 |
| VascepaIcosapent Ethyl | 21 | $12,153 |
| NexletolBempedoic Acid | 18 | $10,356 |
| Rosuvastatin Calcium | 729 | $8,135 |
| Ezetimibe | 355 | $7,324 |
| Metoprolol Succinate | 622 | $6,974 |
| Atorvastatin Calcium | 671 | $5,827 |
| Ranolazine ErRanolazine | 33 | $4,418 |
| Valsartan | 192 | $3,664 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 14 | $3,440 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $62 | $255,741219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 408 cardiovascular disease providers in Indiana.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.